Skip to search formSkip to main contentSkip to account menu

Nelipepimut-S Plus GM-CSF Vaccine

Known as: NeuVax Plus GM-CSF, Nelipepimut-S Plus Sargramostim, HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF 
A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Abstract Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation… 
2017
2017
Background: Our group has been investigating vaccination strategies in breast cancer. Specifically, we have been evaluating HER2… 
2016
2016
1001Background: The role of capecitabine (X) in the adjuvant treatment of BC is not established, and few long-term survival data… 
2016
2016
e274 Background: According to the NCI Office of Cancer Survivorship, in 2014, it is estimated there are 14.5 million cancer… 
2015
2015
Background: In an adjuvant phase II trial, the HER2-derived nelipepimut-S (E75) + GM-CSF vaccine (Neuvax) has been shown to… 
2015
2015
Her2/neu is a validated target in cancer, as various antibodies (Abs) against this antigen have demonstrated their clinical… 
2014
2014
Breast cancer is the most common malignancy in women and even after curative treatment, approximately 10–20% of breast cancer… 
2013
2013
TPS3126 Background: We completed phase I/II clinical trials with NeuVax (nelipepimut-S), a HLA-A2/A3-restricted, HER2-derived… 
2013
2013
Etch pits within olivine grains from the nakhlite meteorites reveal the magnitude and timescale of water-mediated alteration of…